Pfenex Inc (PFNX) Stock Rating Lowered by ValuEngine
ValuEngine downgraded shares of Pfenex Inc (NYSEMKT:PFNX) from a sell rating to a strong sell rating in a research report report published on Friday.
Several other research firms have also weighed in on PFNX. Zacks Investment Research lowered shares of Pfenex from a buy rating to a hold rating in a report on Saturday, July 15th. William Blair reaffirmed an outperform rating on shares of Pfenex in a report on Monday, June 26th.
Pfenex (NYSEMKT:PFNX) opened at 3.52 on Friday. The firm’s 50-day moving average is $4.03 and its 200-day moving average is $4.95. Pfenex has a 1-year low of $3.16 and a 1-year high of $11.35. The firm has a market capitalization of $82.82 million, a price-to-earnings ratio of 56.77 and a beta of 4.65.
Pfenex (NYSEMKT:PFNX) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by $0.06. Pfenex had a negative return on equity of 75.61% and a negative net margin of 406.87%. The firm had revenue of $3.03 million during the quarter, compared to the consensus estimate of $3.10 million. During the same period in the previous year, the company posted ($0.43) EPS. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. On average, equities analysts anticipate that Pfenex will post ($2.09) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Pfenex Inc (PFNX) Stock Rating Lowered by ValuEngine” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/05/pfenex-inc-pfnx-stock-rating-lowered-by-valuengine.html.
In other news, Director Jason Grenfell-Gardner bought 10,000 shares of the stock in a transaction dated Monday, June 12th. The shares were acquired at an average price of $4.51 per share, with a total value of $45,100.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at $45,100. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
A number of large investors have recently modified their holdings of the business. Sanders Morris Harris LLC grew its holdings in Pfenex by 79.9% during the 2nd quarter. Sanders Morris Harris LLC now owns 745,687 shares of the biotechnology company’s stock worth $2,990,000 after acquiring an additional 331,167 shares during the last quarter. FMR LLC grew its holdings in Pfenex by 25.7% during the 1st quarter. FMR LLC now owns 344,677 shares of the biotechnology company’s stock worth $2,003,000 after acquiring an additional 70,577 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Pfenex by 148.5% during the 1st quarter. Renaissance Technologies LLC now owns 325,800 shares of the biotechnology company’s stock worth $1,893,000 after acquiring an additional 194,700 shares during the last quarter. MARSHALL WACE ASIA Ltd bought a new stake in Pfenex during the 1st quarter worth about $1,759,000. Finally, Marshall Wace North America L.P. bought a new stake in Pfenex during the 1st quarter worth about $1,759,000.
Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Stock Ratings for Pfenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex Inc and related stocks with our FREE daily email newsletter.